BMS Logo Bristol-Myers

News

BioNTech, Bristol Myers Squibb and cancer immunotherapy

NJBIZ · 4h

Bristol Myers Squibb, BioNTech partner on $11B cancer drug deal

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Reuters on MSN · 1d

Bristol Myers signs deal worth up to $11.1 billion with BioNTech to develop cancer drug

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb has agreed to pay up to $11.1 billion in a partnership with Germany's BioNTech to develop the latter's next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.

Investopedia on MSN · 1d

BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.

pharmaphorum3d

A history of Bristol-Myers Squibb

Bristol-Myers Squibb was founded in 1858 and has grown ... Around the same time, the prototype of the Squibb logo was designed. The logo represented product uniformity, purity, efficacy and ...

Yahoo Finance1y

Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal

(Reuters) — Bristol-Myers Squibb (BMY) on Sunday said it will acquire cancer drugmaker Mirati Therapeutics (MRTX) for up to $5.8 billion, diversifying its oncology business and adding drugs it ...

Seeking Alpha4d

BMY Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

12d

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors

The stock's fall snapped a four-day winning streak.

Forbes2y

Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?

We believe that Bristol Myers Squibb stock (NYSE: BMY) is currently a better pick than its industry peer, Eli Lilly stock (NYSE: LLY), given its better growth prospects. Eli Lilly is trading at 10 ...

MedCity News4mon

Bristol Myers Squibb

2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results